Antimitogenic polymer drugs based on AMPS: Monomer distribution-bioactivity relationship of water-soluble macromolecules

Biomacromolecules

Volumn 11, Issue 3, 2010, Pages 626-634

  García Fernández, Luis ^a,b   Aguilar, María R ^a,b   Fernández, María M ^c   Lozano, Rosa M ^d   Giménez, Guillermo ^d   Román, Julio San ^a,b  

^a INSTITUTO DE CIENCIA Y TECNOLOGÍA DE POLÍMEROS   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROLIFERATIVE ACTIVITIES; BUTYL ACRYLATES; FGF RECEPTORS; FIBROBLAST GROWTH FACTOR; FREE RADICAL COPOLYMERIZATION; HEPARAN SULFATES; HIGH AFFINITY; IN-SITU; IN-VITRO; INTRACELLULAR SIGNALING; MITOGENIC RESPONSE; N VINYLPYRROLIDONE; POLYMER DRUGS; PROTEOGLYCANS; REACTIVITY RATIO; SEQUENCE DISTRIBUTION; SULFONATED MONOMERS; SULFONIC ACID; SYNTHESIS AND CHARACTERIZATION; TYROSINE KINASE;

AMINO ACIDS; BUTANE; COPOLYMERIZATION; ENDOTHELIAL CELLS; ENZYME ACTIVITY; FREE RADICAL REACTIONS; FREE RADICALS; GENE TRANSFER; MACROMOLECULES; MONOMERS; PHOSPHATASES;

CELL CULTURE;

1 VINYL 2 PYRROLIDINONE; 2 ACRYLAMIDO 2 METHYLPROPANESULFONIC ACID DERIVATIVE; ACIDIC FIBROBLAST GROWTH FACTOR; ACRYLAMIDE DERIVATIVE; ACRYLIC ACID BUTYL ESTER; ACRYLIC ACID COPOLYMER; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; DIOXANE; FREE RADICAL; HEPARIN; MONOMER; POLY(1 VINYL 2 PYRROLIDINONE CO 2 ACRYLAMIDO 2 METHYLPROPANESULFONIC ACID); POLY(ACRYLIC ACID BUTYL ESTER CO 2 ACRYLAMIDO 2 METHYLPROPANESULFONIC ACID); POLYMER; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; GLASS TRANSITION TEMPERATURE; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; MACROMOLECULE; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY; ANIMAL; BAGG ALBINO MOUSE; CELL STRAIN 3T3; CHEMISTRY; DRUG EFFECT; MITOSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SOLUBILITY;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELLS, CULTURED; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; MITOSIS; POLYMERS; SOLUBILITY; WATER;

EID: 77950129893     PISSN: 15257797     EISSN: 15264602     Source Type: Journal    
DOI: 10.1021/bm901194e     Document Type: Article

References (35)

1. Quesada, A. R.; oz, C.; Medina, M. A. Anti-angiogenic drugs: From bench to clinical trials. Med. Res. Rev. 2006, 26 (4), 483-530.
2. Zhong, H.; Bowen, J. P. Antiangiogenesis drug design: Multiple pathways targeting tumor vasculature. Curr. Med. Chem. 2006, 13 (8), 849-862.
3. Wheatley-Price, P.; Shepherd, F. A. Targeting angiogenesis in the treatment of lung cancer. J. Thorac. Oncol. 2008, 3 (10), 1173-1184.
4. Petersen, I. Antiangiogenesis, anti-VEGF(R) and outlook. In Targeted Therapies in Cancer; Dietel, M., Ed.; Springer: Berlin, 2007; Vol.XIV, pp 189-199.
5. Auguste, P.; Javerzat, S.; Bikfalvi, A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res. 2003, 314 (1), 157-166.
6. Mach, H.; Volkin, D. B.; Burke, C. J.; Russell Middaugh, C.; Linhardt, R. J.; Fromm, J. R.; Loganathan, D.; Mattsson, L. Nature of the interaction of heparin with acidic fibroblast growth factor. Biochemistry 1993, 32 (20), 5480-5489.
7. Spivak-Kroizman, T.; Lemmon, M. A.; Dikic, I.; Ladbury, J. E.; Pinchasi, D.; Huang, J.; Jaye, M.; Crumley, G.; Schlessinger, J.; Lax, I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994, 79 (6), 1015-1024.
8. Waksman, G.; Herr, A. B. New insights into heparin-induced FGF oligomerization. Nat. Struct. Mol. Biol. 1998, 5 (7), 527-530.
9. Gagliardi, A. Inhibition of angiogenesis by suramin. Cancer Res. 1992, 52 (18), 5073-5075.
10. Ganesh, V. K.; Muthuvel, S. K.; Smith, S. A.; Kotwal, G. J.; Murthy, K. H. M. Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein. Biochemistry 2005, 44 (32), 10757-10765.
11. Kathir, K. M.; Kumar, T. K. S.; Yu, C. Understanding the mechanism of the antimitogenic activity of suramin. Biochemistry 2006, 45 (3), 899-906.
12. Meyers, M. O.; Gagliardi, A. R.; Flattmann, G. J.; Su, J. L.; Wang, Y. Z.; Woltering, E. A. Suramin analogs inhibit human angiogenesis in vitro. J. Surg. Res. 2000, 97 (2), 130-134.
13. Middaugh, C. R.; Mach, H.; Burke, C. J.; Volkin, D. B.; Dabora, J. M.; Tsai, P. K.; Bruner, M. W.; Ryan, J. A.; Marfia, K. E. Nature of the interaction of growth factors with Suramin. Biochemistry 1992, 31 (37), 9016-9024.
14. Liekens, S.; Neyts, J.; Dégrève, B.; De Clercq, E. The sulfonic acid polymers PAMPS [Poly(2-acrylamido-2-methyl-l-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis. Oncol. Res. 1997, 9 (4), 173-181.
15. 1H NMR monitoring of monomer consuption: a simple and fast way of stimating reactivity ratios. Macromolecules 2002, 35, 2036-2041.
16. Fernández-Tornero, C.; Lozano, R. M.; Redondo-Horcajo, M.; Gómez, A. M.; López, J. C.; Quesada, E.; Uriel, C.; Valverde, S.; Cuevas, P.; Romero, A.; Giménez-Gallego, G. Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity. Crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalenesulfonate. J. Biol. Chem. 2003, 278 (24), 21774-21781.
17. Aguilar, M. R.; Gallardo, A.; San Román, J.; Cifuentes, A. Micellar electrokinetic chromatography (MEKC): A powerful analytical tool to study copolymerisation reactions involving ionic species. Macromolecules 2002, 35, 8315-8322.
18. 1H NMR monitoring. Polymer 2005, 46 (7), 2040-2046.
19. López Donaire, M. L.; Parra-Cáceres, J.; Vázquez-Lasa, B.; GarcíaÁlvarez, I.; Fernández- Mayóralas, A.; López-Bravo, A.; San Román, J. Polymeric drugs based on bioactive glycosides for the treatment of brain tumours. Biomaterials 2009, 30 (8), 1613-1626.
20. Gallardo, A.; Aguilar, M. R.; Abraham, G.; San Román, J. Chain copolymerization reactions: an algorithm to predict the reaction evolution with conversion. J. Chem. Educ. 2004, 87, 1210-1215.
21. Kurenkov, V. F.; Khabibullina, G. Z.; Zaitseva, N. N. Radical copolymerization of sodium 2-acrylamido-2-methyl-2- propanesulfonate with N-vinyl-2-pyrrolidone in water and aqueous salt solutions. Russ. J. Appl. Chem. 2002, 75 (11), 1855-1858.
22. Kurenkov, V. F.; Zaitseva, N. N.; Zhelonkina, T. A.; Lobanov, F. I. Degradation of copolymers of N-vinylpyrrolidone with sodium 2-acrylamido-2- methylpropanesulfonate in aqueous solutions. Russ. J. Appl. Chem. 2003, 76 (6), 981-984.
23. Kurenkov, V. F.; Zhelonkina, T. A. Copolymerization of sodium 2-acrylamido-2-methylpropanesulfonate with N-vinylpyrrolidone in water and dimethyl sulfoxide. Russ. J. Appl. Chem. 2004, 77 (2), 307-312.
24. Kurenkov, V. F.; Zhelonkina, T. A.; Kovalenko, V. I. Concentration effect in copolymerization of sodium 2-acrylamido-2- methylpropanesulfonate with N-vinylpyrrolidone in aqueous solutions. Russ. J. Appl. Chem. 2005, 78 (2), 295-300.
25. Alencar de Queiroz, A. A.; Gallardo, A.; San Román, J. Vinylpyrrolidone-N, N-dimethylacrylamide water-soluble copolymers: synthesis, physical-chemical properties and proteic interactions. Biomaterials 2000, 27, 1631-1643.
26. Satchi-Fainaro, R.; Duncan, R.; Barnes, C. M. Polymer therapeutics for cancer: Current status and future challenges. In Polymer Therapeutics II; Heidelberg, S. B., Ed.; Springer: Berlin, 2006; Vol.193, pp 1-65.
27. Vicent, M. J.; Duncan, R. Polymer conjugates: Nanosized medicines for treating cancer. Trends Biotechnol. 2006, 24 (1), 39-47.
28. Duncan, R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway. Pharm. Sci. Technol. Today 1999, 2 (11), 441-449.
29. Hattori, K.; Yoshida, T.; Nakashima, H.; Premanathan, M.; Aragaki, R.; Mimura, T.; Kaneko, Y.; Yamamoto, N.; Uryu, T. Synthesis of sulfonated amino-polysaccharides having anti-HIV and blood anticoagulant activities. Carbohydr. Res. 1998, 312, 1-8.
30. Fougnot, C.; Jozefowicz, M.; Samama, M.; Bara, L. New heparinlike insoluble materials: Part II. Ann. Biomed. Eng. 1979, 7 (5), 441-450.
31. Beugeling, T.; Van Der Does, L.; Bantjes, A.; Sederel, W. L. Antithrombin activity of a polyelectrolyte synthesized from cis-1,4polyisoprene. J. Biomed. Mater. Res. 1974, 8 (6), 375-379.
32. Jonca, F. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J. Biol. Chem. 1997, 272 (39), 24203-24209.
33. Mandriota, S. J. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 1997, 110 (18), 2293-2302.
34. Lozano, R. M.; Jiménez, M. A.; Santoro, J.; Rico, M.; GiménezGallego, G. Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalenetrisulfonate: A minimal model for the anti-tumoral action of suramins and suradistas. J. Mol. Biol. 1998, 287 (5), 899-915.
35. Liekens, S.; Leali, D.; Neyts, J.; Esnouf, R.; Rusnati, M.; Dell'era, P.; Maudgal, P. C.; De Clercq, E.; Presta, M. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol. Pharmacol. 1999, 56 (1), 204-213.